About Medisieve limited
Medisieve Limited: A Revolutionary Solution for Blood-Borne Diseases
Medisieve Limited is a UK-based medical technology company that has developed a revolutionary solution for blood-borne diseases. The company was founded in 2015 by Dr. George Frodsham, who was inspired to create a device that could remove malaria-infected red blood cells from the bloodstream after witnessing the devastating effects of the disease during his travels in Africa.
The Medisieve device uses magnetic nanoparticles to selectively capture and remove infected cells from the bloodstream, allowing healthy cells to remain and continue their vital functions. This innovative approach has the potential to transform the treatment of a wide range of blood-borne diseases, including malaria, sepsis, and COVID-19.
Medisieve's technology has already attracted significant attention from investors and healthcare professionals alike. In 2018, the company raised £1.2 million in seed funding from investors including 24Haymarket and Innovate UK. The following year, Medisieve was awarded a grant of £1 million by the Bill & Melinda Gates Foundation to develop its malaria treatment further.
One of Medisieve's key advantages is its versatility - its technology can be adapted for use with different types of blood-borne diseases simply by changing the specific magnetic nanoparticles used in each case. This means that it has enormous potential as a platform technology that could be applied across multiple disease areas.
Another advantage is that Medisieve's device can be used alongside existing treatments rather than replacing them entirely - this means that it could potentially improve outcomes for patients without requiring major changes to existing healthcare systems or practices.
In addition to its core technology development work, Medisieve is also actively engaged in clinical trials and partnerships with leading healthcare organizations around the world. For example, it recently announced a collaboration with Imperial College London on an early-stage trial using its device as part of an extracorporeal membrane oxygenation (ECMO) system for COVID-19 patients.
Overall, Medisieve Limited is a company with enormous potential to transform the treatment of blood-borne diseases. Its innovative technology, strong partnerships, and impressive track record of funding and investment make it a company to watch in the coming years.